Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781682 | 0.87 | KMO (0.56) | PNMTKMOMEN1KMT2AFDFT1 | |
| SCHEMBL4619729 | 0.81 | KMO (0.51) | PNMTKMOMEN1KMT2AFDFT1 | |
| SCHEMBL6005581 | 0.80 | PNMT (0.58) | PNMTGRNSORT1KMOFDFT1 | |
| SCHEMBL6003855 | 0.80 | PNMT (0.58) | PNMTGRNSORT1KMOFDFT1 | |
| SCHEMBL5130053 | 0.80 | PNMT (0.58) | PNMTGRNSORT1KMOFDFT1 | |
| SCHEMBL6005368 | 0.80 | KMO (0.48) | PNMTKMOMEN1KMT2AFDFT1 | |
| SCHEMBL4983468 | 0.80 | PNMT (0.50) | PNMTGRNSORT1KMOMEN1 | |
| SCHEMBL4439324 | 0.78 | PNMT (0.53) | PNMTKMOTSHR | |
| SCHEMBL6006032 | 0.78 | PNMT (0.54) | PNMTGRNSORT1FDFT1TSHR | |
| SCHEMBL6005266 | 0.77 | KMO (0.48) | PNMTKMOMEN1KMT2AFDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | PNMT 479/4885GRN 1030/4885SORT1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.